Add BrightSurf on Google Email

JCI table of contents May 1, 2005

A novel vaccine against Pseudomonas aeruginosa has been successfully tested in mice, inducing antibody production and protection against the deadly bacteria. The vaccine uses a modified adenovirus vector expressing a region of the bacteria's outer membrane, which was previously recognized as a promising vaccine candidate.

SourceJCI Journals·JournalJournal of Clinical Investigation·DateApr 1, 2005

New vaccine means bye-bye to bacteria in the lung

A novel genetic vaccine against Pseudomonas aeruginosa has been developed using a modified adenovirus vector expressing a region of the outer membrane called OprF. Immunization with this vaccine induces antibody production and protects mice from deadly doses of the bacteria, even after repeated exposure.

SourceJCI Journals·JournalJournal of Clinical Investigation·DateApr 1, 2005

Risk factors affect parents' attitudes about STD vaccinations

A study published in Archives of Pediatrics and Adolescent Medicine found that parental attitudes toward STD vaccinations are not significantly influenced by the type of infection, with most parents prioritizing vaccine effectiveness and prevention of fatal infections. Only 6% of parents expressed an aversion to STD vaccines in general.

SourceIndiana University·JournalArchives of Pediatrics and Adolescent Medicine·DateFeb 8, 2005

Mayo Clinic study suggests no link between autism and immunizations

A Mayo Clinic study analyzed data from the Rochester Epidemiology Project and found a stable incidence of autism until 1988-1991, then increased with new diagnostic criteria and special education laws. Researchers identified 124 children meeting current diagnostic criteria for autism out of 3,000 with related diagnoses.

SourceMayo Clinic·JournalArchives of Pediatrics and Adolescent Medicine·DateJan 3, 2005

Vaccinating wildlife can reduce human risk for Lyme disease

A four-year study by Yale researchers found that vaccinating white-footed mice reduced the number of deer ticks carrying Lyme disease. The study demonstrated a significant reduction in risk for humans getting Lyme disease from tick bites, but not as great as expected. Further development of oral vaccines is proposed to reduce human risk.

SourceYale University·JournalProceedings of the National Academy of Sciences·DateDec 13, 2004

Early results show promise for strep vaccine

A phase 1 vaccine trial has demonstrated that a group A streptococcal vaccine appears safe and well-tolerated, inducing immune responses capable of conferring protection against multiple strains. The study's findings suggest that a specific dose and schedule may be effective in preventing group A streptococcal infections.

SourceJAMA Network·JournalJAMA·DateAug 10, 2004

New technology blocks gene to increase immune response against deadly brain tumor cells

Researchers at Cedars-Sinai Medical Center have developed a new approach to boost the immune response against gliomas, a type of brain tumor. By targeting the interleukin 10 gene in dendritic cells, they can increase the production of IL-12, leading to a stronger Th1 response and enhanced immune response against cancer cells.

SourceCedars-Sinai Medical Center·JournalEuropean Journal of Immunology·DateMay 24, 2004